Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Camp4 Therapeutics (CAMP) EBITDA: 2023-2024

Historic EBITDA for Camp4 Therapeutics (CAMP) over the last 2 years, with Dec 2024 value amounting to -$51.8 million.

  • Camp4 Therapeutics' EBITDA fell 11.98% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.4 million, marking a year-over-year decrease of 3.68%. This contributed to the annual value of -$51.8 million for FY2024, which is 5.07% down from last year.
  • Per Camp4 Therapeutics' latest filing, its EBITDA stood at -$51.8 million for FY2024, which was down 5.07% from -$49.3 million recorded in FY2023.
  • In the past 5 years, Camp4 Therapeutics' EBITDA registered a high of -$49.3 million during FY2023, and its lowest value of -$51.8 million during FY2024.
  • Its 2-year average for EBITDA is -$50.5 million, with a median of -$50.5 million in 2023.
  • Data for Camp4 Therapeutics' EBITDA shows a maximum YoY dropped of 5.07% (in 2024) over the last 5 years.
  • Camp4 Therapeutics' EBITDA (Yearly) stood at -$49.3 million in 2023, then declined by 5.07% to -$51.8 million in 2024.